MONASH UNIVERSITY

Monash University has established the Monash Boston Hub in Cambridge to deepen collaborations with North American and European biotech companies for drug discovery and health innovations.

Researchers from Monash University and The Alfred Hospital have developed Entelli-02, a five-phage cocktail specifically designed to target Enterobacter cloacae complex bacteria, which caused over 200,000 deaths globally in 2019.

Percheron Therapeutics has appointed Dr Eugene Kennedy as Chief Medical Officer and Valentina Dubljevic as Chief Technology Officer to strengthen leadership ahead of HMBD-002's phase II trial.

Immuron achieved record global revenue of $7.3 million in FY2025, representing a 49% increase driven by strong growth in its traveler's diarrhea product Travelan.

A retrospective analysis of 6,217 CLL patients in Australia found that regular immunoglobulin replacement therapy was not associated with reduced risk of serious infections requiring hospitalization.

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

A large observational study of 13,811 women with early-stage breast cancer found that aprepitant, a commonly prescribed anti-nausea medication, was associated with an 11% lower risk of cancer recurrence and 17% lower risk of breast cancer-related death.

The phase 3 BM12 CAST trial demonstrated that cyclophosphamide plus cyclosporin significantly improved graft-versus-host disease-free relapse-free survival compared to standard cyclosporin/methotrexate prophylaxis in blood cancer patients.

Immuron is on track to exceed A$7 million in sales this financial year, representing a significant increase from the previous year's A$4.9 million.

Melbourne-based PolyActiva raised $40 million in Series C funding, including $27 million from Australia's National Reconstruction Fund, to advance its biodegradable glaucoma treatment implant.